Table 1 Collected parameters in Super-Responders (SR) and Non-Responders (NR) with the respective answer possibilities

Demographic data

 Age at initiation of treatment with CGRP(-R) mAbs

Age in years

 Sex

Female/Male

Migraine: Disease characteristics

 Disease duration

Time since migraine onset in years

 Type of migraine prior to mAb treatment

Episodic/Chronic

 Aura

Yes/No

 Monthly headache days (MHD) at baseline

Number of days ≤ 28

 Monthly migraine days (MMD) at baseline

Number of days ≤ 28

 Non-migraine days (NMD) at baseline

Number of days ≤ 28

Migraine: Symptoms during the attacks

 Average untreated attack

Duration in hours

 Average untreated pain intensity

Numeric analogue scale 0–10

 Unilateral location

Yes/No

 Pulsating quality

Yes/No

 Aggravation by physical activity

Yes/No

 Nausea

Yes/No

 Vomiting

Yes/No

 Photophobia

Yes/No

 Phonophobia

Yes/No

Migraine: Acute and preventive treatment

 Use of triptans as acute treatment

Yes/No

 Subjective good response to triptans

Yes/No

 Number of prior preventive substances

Number

 For NR: Following treatment strategy

Name of medication

General medical history

 Concomitant depression

Yes/No

 Concomitant anxiety disorder

Yes/No

 Concomitant other chronic pain condition

Yes/No

 Concomitant medication overuse headache (MOH)

Yes/No